Verisim Life uses AI-powered biosimulations to replace animal drug testing

News Feed

The global drug discovery market is today estimated to be worth at least $35 billion, a figure that could rise to $71 billion by 2025. But getting a drug from research and development through to market is a long and resource-intensive process.

A large part of this involves rigorous testing to ensure that a drug is not only effective, but safe — and this unfortunately entails animal testing, be it monkeys, rats, mice, dogs, or rabbits. Contrary to what some may think, animal testing is not only a pivotal facet of drug development, it’s actually a legal requirement in most countries before clinical trials can begin on humans. However, animal testing is slow, expensive, and ultimately has a low success rate — it’s estimated that less than 10% of drug candidates that are tested on animals make it through the pipeline.

And it’s against that backdrop that Verisim Life (“Verisim”),


This article was originally published on on VentureBeat.

Click here to read the rest of the article.


Leave a Comment

Start typing and press Enter to search